drugset / Trial / NCT00463684
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
Phase 4
Completed
278 enrolled
PATH
Mahidol University · collabMinistry of Health, Sri Lanka · collabQuintiles Singapore · collab
NaSingle-groupOpen-labelPrevention
Summary
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and measles vaccine at 9 months of age. The primary hypothesis was that the seropositivity rate at 28 days post vaccination in Japanese Encephalitis (JE) and measles concomitantly vaccinated subjects 9 months of age is greater than 80% for JE and greater than 90% for measles.
Timeline
- Start
- 2007-07-07
- Primary completion
- 2007-11-07
- Completion
- 2008-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Live, attenuated measles vaccine | Vaccine | — | Subcutaneous |
| Subject | SA 14-14-2 Japanese encephalitis vaccine | Vaccine | — | Subcutaneous |